Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision-Making
Joseph Hackett(Center for Devices and Radiological Health), Ronald A. Salerno, Shiew‐Mei Huang(United States Food and Drug Administration), Jerry M. Collins(National Institutes of Health), C. Brazell(GlaxoSmithKline (Germany)), Joanne Killinger, Timothy S. Anderson(University of California, San Francisco), Lawrence J. Lesko(University of Florida), Donald C. Anderson(Children's Hospital of Philadelphia), Brian B. Spear(Abbott Fund), Andrew J. Dorner, Baltazar Gomez‐Mancilla(Novartis (Switzerland)), David M. Essayan(Center for Biologics Evaluation and Research), Susan Ide(Novartis (United States))
Cited by 1
Related Papers
Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23
|Science|1996|784
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrodental dysostosis
|Nature Genetics|2000|358
Deprescribing in Older Adults With Cardiovascular Disease
|Journal of the American College of Cardiology|2019|201